

The following schedule presents fiscal 2010 and 2009 reportable segment operating income by quarter consistent with the presentation of annual fiscal 2010 and 2009 reportable segment operating income in our Annual Report on Form 10-K for the fiscal year ended September 24, 2010 (our “Form 10-K”).

In our Form 10-K, and in the attached schedule, certain costs that were previously included in corporate expense, primarily stock-based compensation expense, are now reflected in the Company’s reportable segments, consistent with the way management currently measures and evaluates segment performance.

In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include income related to sales of oxycodone hydrochloride extended-release (Oxy ER) tablets sold under a license agreement, which began in the fourth quarter of fiscal 2008 and ended in the second quarter of fiscal 2009, charges associated with acquisitions, divestitures and licensing fees, certain legal and environmental charges, and restructuring charges incurred under the Company’s 2007 and 2009 restructuring programs. Although these amounts are excluded from segment operating income, as applicable, they are included in consolidated operating income reported in our Form 10-K.

Covidien plc  
January 31, 2011

**Covidien plc**  
**Operating Income**  
(dollars in millions)

	Fiscal 2010 Quarters Ended				Fiscal 2009 Quarters Ended			
	September 24, 2010	June 25, 2010	March 26, 2010	December 25, 2009	September 25, 2009	June 26, 2009	March 27, 2009	December 26, 2008
Medical Devices	\$ 548	\$ 512	\$ 508	\$ 529	\$ 486	\$ 481	\$ 439	\$ 443
Pharmaceuticals	62	83	101	84	79	91	101	72
Medical Supplies	46	70	71	67	55	68	59	43
Operating income of reportable segments	656	665	680	680	620	640	599	558
Unallocated amounts:								
Corporate expenses	(108)	(96)	(109)	(106)	(94)	(105)	(111)	(82)
Restructuring charges	(20)	(25)	(26)	(5)	(44)	(5)	(9)	(3)
Legal and environmental charges, including shareholder settlements	-	-	-	(33)	(111)	-	(183)	(36)
Charges associated with acquisitions, divestitures and licensing arrangements	(85)	(5)	-	-	(57)	(89)	(20)	-
Impact of Oxy ER <sup>(1)</sup>	-	-	-	-	-	-	251	94
<b>Consolidated Operating Income</b>	<b>\$ 443</b>	<b>\$ 539</b>	<b>\$ 545</b>	<b>\$ 536</b>	<b>\$ 314</b>	<b>\$ 441</b>	<b>\$ 527</b>	<b>\$ 531</b>

<sup>(1)</sup> Represents the sales and direct costs attributable to selling oxycodone hydrochloride extended-release tablets (Oxy ER).